Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪14.74 B‬USD
‪249.70 M‬USD
‪1.89 B‬USD
‪98.41 M‬
Beta (1Y)

About Neurocrine Biosciences, Inc.

Kevin Charles Gorman
San Diego
Employees (FY)
‪1.4 K‬
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where NBIX is featured.

Frequently Asked Questions

The current price of NBIX is 148.24 USD — it has increased by 1.19% in the past 24 hours. Watch Neurocrine Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neurocrine Biosciences, Inc. stocks are traded under the ticker NBIX.
NBIX stock has risen by 7.23% compared to the previous week, the month change is a 9.65% rise, over the last year Neurocrine Biosciences, Inc. has showed a 52.34% increase.
We've gathered analysts' opinions on Neurocrine Biosciences, Inc. future price: according to them, NBIX price has a max estimate of 216.00 USD and a min estimate of 111.00 USD. Watch NBIX chart and read a more detailed Neurocrine Biosciences, Inc. stock forecast: see what analysts think of Neurocrine Biosciences, Inc. and suggest that you do with its stocks.
NBIX reached its all-time high on Mar 21, 2024 with the price of 148.37 USD, and its all-time low was 1.94 USD and was reached on Nov 30, 2009. View more price dynamics on NBIX chart.
See other stocks reaching their highest and lowest prices.
NBIX stock is 1.70% volatile and has beta coefficient of 0.59. Track Neurocrine Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neurocrine Biosciences, Inc. there?
Today Neurocrine Biosciences, Inc. has the market capitalization of ‪14.74 B‬, it has increased by 5.78% over the last week.
Yes, you can track Neurocrine Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Neurocrine Biosciences, Inc. is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
NBIX earnings for the last quarter are 0.42 USD per share, whereas the estimation was 1.10 USD resulting in a −61.75% surprise. The estimated earnings for the next quarter are 1.16 USD per share. See more details about Neurocrine Biosciences, Inc. earnings.
Neurocrine Biosciences, Inc. revenue for the last quarter amounts to ‪515.30 M‬ USD, despite the estimated figure of ‪512.40 M‬ USD. In the next quarter, revenue is expected to reach ‪546.76 M‬ USD.
NBIX net income for the last quarter is ‪43.40 M‬ USD, while the quarter before that showed ‪147.70 M‬ USD of net income which accounts for −70.62% change. Track more Neurocrine Biosciences, Inc. financial stats to get the full picture.
No, NBIX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 12, 2024, the company has ‪1.40 K‬ employees. See our rating of the largest employees — is Neurocrine Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neurocrine Biosciences, Inc. EBITDA is ‪492.90 M‬ USD, and current EBITDA margin is 22.05%. See more stats in Neurocrine Biosciences, Inc. financial statements.
Like other stocks, NBIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neurocrine Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neurocrine Biosciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neurocrine Biosciences, Inc. stock shows the strong buy signal. See more of Neurocrine Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.